Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine for Substance Abuse in Schizophrenia
NCT00295412Phase 4Completed
- Sponsor
- Université de Montréal
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quetiapine in schizophrenia and substance use disorder (SUD), sponsored by Université de Montréal. Primary endpoint: Decrease in drug cravings at 12 weeks. Status: completed.
02
Drugs
quetiapine
03
Conditions
schizophreniasubstance use disorder (SUD)
Beyond the preview
Go deeper on NCT00295412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295412.